ERIC BENEVICH - 31 Jan 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Commercial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
31 Jan 2026
Net transactions value
-$175,790
Form type
4
Filing time
03 Feb 2026, 18:21:32 UTC
Previous filing
16 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BENEVICH ERIC Chief Commercial Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 03 Feb 2026 0001643653

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2,294 +4.4% $0.000000 54,047 31 Jan 2026 Direct
transaction NBIX Common Stock Tax liability $175,790 -1,292 -2.4% $136.06 52,755 31 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,294 -100% $0.000000 0 31 Jan 2026 Common Stock 2,294 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and vested as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award.